ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2024

Salivary Gland Ultrasound May Lead to a More Accurate Stratification of Patients with the Same Serological Profile in Sjögren’s Syndrome: Towards a Personalized Approach
Abstract Number: 0136

Sarcoidosis Incidence After mTOR Inhibitor Treatment
Abstract Number: 1111

Sarcoidosis Rates in BCG-Vaccinated and Unvaccinated Young Adults: A Danish Register-Based Study
Abstract Number: 0160

Sarcopenia in Myositis Patients: A Marker of Muscle Damage Associated with Myositis Severity and Disability
Abstract Number: 1676

Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Abstract Number: 0511

SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Abstract Number: 0796

SARS-CoV-2 Vaccine in Axial Spondyloarthritis and Psoriatic Arthritis: Does Sulfasalazine Counterbalance TNFI Impaired Immunogenicity?
Abstract Number: 0993

SARS-CoV-2 Vaccine Side Effects and Infections in SLE
Abstract Number: 0566

SARS-CoV-2-Specific T Cell Responses in Multisystem Inflammatory Syndrome in Children
Abstract Number: 1343

Satisfaction with Rheumatoid Arthritis Care Is Related to Discordance with Providers’ Treatment Goals and Patients’ Reasons for Disagreement
Abstract Number: 1836

Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis
Abstract Number: 1166

Scleroderma Fibroblasts Induce Alternative Macrophage Activation via an ERK1/2-dependent Mechanism
Abstract Number: 1046

Scleroderma Heart Disease
Abstract Number: 1530

Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortality
Abstract Number: 2155

Sclerodermoid Reaction Following Immune Checkpoint Inhibitor Therapy: A Case Series from MD Anderson Cancer Center

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].